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During the 2004 International Congress of Immu-
nology in Montreal, a panel of experts gathered for
an “Ideashop” discussion on the potential role of in-
nate immunity in autoimmunity and the ways in
which this might be targeted in future therapies.
 
Given the importance of innate immunity in the activa-
tion of conventional immune responses, a role for innate
immunity in the development of autoimmunity is antici-
pated. The challenge is to identify which cells, receptors,
and mediators are critical in different autoimmune settings.
Recently, it has been suggested that the TLRs, which are
classically thought of as sensors of microbial components,
may have the potential to recognize self-antigens and trigger
autoimmune disease (1). And the activating NK receptors
expressed on CD8
 
 
 
 T cells may have a hand in the devel-
opment of autoimmune diabetes (2). The inherent, low-
level autoreactivity of certain specialized immune cell types
which have both innate and adaptive characteristics, such as
the CD1-restricted NKT cells, 
 
  
 
 T cells, and B1 cells,
suggests that they may also have the potential to stimulate
autoimmunity, but there is little direct evidence at this
stage. What was more unexpected, and still controversial at
this point, is the potential regulatory role of these innate
lymphocytes, with some groups reporting that NKT cells
can protect against the development of autoimmune disease
(3). Ideashop organizers, Matthias Von Herrath and Eli
Sercarz, and sponsor, Kirin Brewery, hoped that a round-
table discussion of the new data and concepts would help
clarify some of the uncertainties, suggest new research di-
rections, and stimulate ideas for future therapies. Sadly, not
all of the topics that were discussed could be presented, but
here are some of the highlights.
 
NKT Cells as Regulators of Autoimmunity
Jean-François Bach: 
 
There are data, and we contributed
to it initially, showing that autoimmune strains—NOD
mice, SJL mice (4), and lupus-prone mice—are somewhat
deficient in NKT cells, both in number and function (5).
In addition, one can prevent autoimmunity by a number of
maneuvers that aim to boost NKT cells (6, 7). But there are
also discrepant data. It would be nice to hear the opinion of
the experts on this topic which relates to the more general
problem of what is the involvement of NKT cells in regu-
lation of immune responses?
 
Albert Bendelac: 
 
We have tried to explore this area and
have had several results that are conflicting with others.
Some of the most crucial data indicating that NKT cells are
important in type-1 diabetes relies on crossing CD1d-deficient
mice to the appropriate background, and there are different
results from different laboratories. Obviously, one of the
major issues here is the carrying of background genes that
modify these diseases. That is very much true for diabetes, I
think, and explains why there is such a discrepancy in the field.
 
J-FB: 
 
The NOD mice, when they are backcrossed to
CD1d knock-out mice have been claimed to show en-
hanced disease expression, which indicated that NKT cells
play a role in the physiological control of autoimmunity.
But more recently, when we backcrossed the mice further
we lost that difference (8, 9). Now, in collaboration with
Masuru Taniguchi, we have crossed V
 
 
 
14-deficient mice
 
*
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and NOD mice, and again, there was no disease accelera-
tion (unpublished data). A complicating factor is the ex-
tremely important influence of sanitary conditions on the
expression of this autoimmune disease. Were the sanitary
conditions different (10), or was there a problem with the
initial backcrossed mice? I don’t know.
 
Matthias G. von Herrath: 
 
Let us say there is no differ-
ence in diabetes incidence between CD1d-deficient mice
and NOD mice. This doesn’t mean that NKT cells would
not be a useful therapeutic tool. A similar consideration ap-
plies to the role of IL-4 in the diabetogenic process. Data in
NOD mice and RIP-LCMV mice models are very clear in
showing that physiological IL-4 production does not play
any role during the diabetogenic process. However, IL-4
has been shown to have strong beneficial effects in both
models (11, 12). Regarding NKT cells, the efficacy of ther-
apy may depend on the set point in the peripheral blood.
As I understand, there is considerable variation in NKT cell
numbers between human individuals (13). So if we en-
hance NKT cells therapeutically, will we have to watch
these set points and subclassify the patients in order to de-
fine those that might be responsive to this form of therapy?
 
AB: 
 
When we looked at humans with specific probes to
identify NKT cells, we found extravagant differences (as
much as a thousand-fold) between individuals. Some have
virtually no NKT cells and others have 1–3% of peripheral
blood lymphocytes (13). We looked at identical twins and
they have exactly the same frequency of NKT cells. I have
looked at my own for a couple of years now—they don’t
change, and it is the same for many other people. So every-
body has a set frequency of NKT cells; it is genetically de-
termined and it is set for life. Going to clinical trials, we
will have to be extremely careful in terms of first determin-
ing the frequency of the cells and understanding the conse-
quences of having a low or high level of NKT cells.
 
J-FB: 
 
There was some data initially in favor of the role of
NKT cells in immunoregulation, particularly in the context
of the Th1/Th2 paradigm (7). What would you say today?
 
Mitchell Kronenberg: 
 
Our research suggests that these
cells are poised or programmed to make both IL-4 and
IFN-
 
 
 
, and that puzzles us. When we stimulate them
through the T cell receptor, their immediate response is to
make both cytokines (14, 15). Even with compounds that
are reported to stimulate a Th2 response such as OCH we
see immediately that NKT cells will make both cytokines.
But we do find that the sustained IFN-
 
 
 
 that we expect to
see in the serum is diminished with OCH compared with
 
 
 
-gal-cer. Perhaps they have communicated differently
with DCs and ultimately with NK cells, which are the ma-
jor producers of IFN-
 
 
 
, we believe, following the activa-
tion of NKT cells. So it may be possible to manipulate the
NKT cell response by using different ligands. The other
thing that is important is that if you activate NKT cells not
through the T cell receptor solely or primarily but through
other receptors, such as the IL-12 receptor, they don’t
make much IL-4 and they make more IFN-
 
 
 
 (16). So per-
haps NKT cells can integrate the signals from different re-
ceptors that in the end might push the overall immune re-
sponse in the Th1 or Th2 direction.
 
Are Innate Lymphocytes Drivers of Autoimmunity?
Michael B. Brenner: 
 
It’s very important to keep in mind
that NKT cells are there primarily to fight infection. We
need to learn how they are activated in a variety of micro-
bial encounters in order to understand the circumstances in
which they are activated under physiological conditions.
We also have to think about cognate antigen recognition.
All evidence indicates that they are largely reactive to self-
antigens. A variety of studies have underscored that the
CD1d molecule picks up self-lipids based on where it traf-
fics. This is a set up for cognate antigen recognition where
the autoimmunity is not so much determined by the im-
munoregulatory aspects of NKT cells, but the cross-reac-
tivity or over-activity on self-antigens in the context of
molecular mimicry of foreign antigens. Thus, I would em-
phasize that there are two ways that NKT cells might be
involved in autoimmune disease: the one that has just been
discussed, and the other where they are actually the driver
of autoimmunity through self-reactivity.
 
Mark J. Shlomchik: 
 
What cell types do you imagine
NKT cells are recognizing CD1d on, in that case?
 
MBB: 
 
Most of what we know, with a few exceptions,
comes from studies in mice, which have only CD1d.  In
humans, we must also consider CD1a, b and c.  All of these
molecules are know to recognize foreign microbial anti-
gens. Yet, there is evidence that they also recognize self-
glycolipids. Correspondingly, there is the potential for
CD1a, b, and c foreign reactive T cells to also be self-reac-
tive and to mediate autoimmunity, again based on cognate
antigen reactivity.  CD1a, b, and c are expressed almost
exclusively on professional APCs, mainly dendritic cells,
CD1c is also on B cells, and thus expression is more similar
to MHC class II than MHC class I.  In contrast, CD1d has
a broader distribution including expression on both mye-
loid cells and some epithelial cells.
 
MGvH:
 
 What is known about these self CD1 ligands in
terms of their potentially pathogenic presentation during
inflammatory processing?
 
MBB:
 
 I don’t have any data on that, perhaps Gennaro
[GDL] does?
 
Gennaro De Libero:
 
 First, I would like to broaden the
discussion to include not only NKT cells but also other T
cells that recognize other types of self-antigens. We must
not forget 
 
  
 
 T cells in humans, for example, which recog-
nize phosphorylated metabolites. We should also not forget
MAIT cells in the gut and other types of autoreactive T
cells that recognize other types of self-ligands such as gly- 
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cosphingolipid. We have recent data showing that if you
stimulate antigen-presenting cells, like dendritic cells or
macrophages, with pathogenic bacteria or different types of
microbial components which are known to stimulate
TLRs, you end up with a complete change in the metabo-
lism of lipids (unpublished data). This leads to up-regula-
tion of the synthesis of defined glycosphingolipids, and
these APCs become capable of stimulating autoreactive T
cells. There is an effect due to up-regulation of costimula-
tion molecules; however, it is not sufficient. What we need
for activation is this modification of lipid metabolism.
 
MBB:
 
 This is the concept of neo-self epitopes.
 
GDL:
 
 Yes, this is a kind of induced self-recognition. More
self or perhaps slightly modified self is induced and so you
get activation of these autoreactive cells.
 
AB:
 
 To extend what Gennaro [GDL] is saying, the notion
of innate lymphocytes is a bit paradoxical when we talk
about T cells, B1 cells, 
 
  
 
 T cells, and NKT cells. They ex-
press rearranging receptors, so why would we call them in-
nate? The innate characteristics come from several aspects.
One is the sequence of the antigen receptor, which is germ-
line encoded. You don’t need any special manipulation of
the genome to make the sequence, which has been likely
evolutionarily selected from an ancient receptor. Then,
there is the autoreactivity. They do not explode when you
put them in presence of antigen-presenting cells, but there
is a degree of autoreactivity. I believe that this autoreactiv-
ity is under the control of inhibitory receptors, such as NK
inhibitory receptors in 
 
  
 
 T cell and NKT cells. Finally,
another aspect that brings them together very nicely is the
fact that if you take the antigen receptor from a B1 cell, 
 
  
 
T cell, or NKT cell and make a transgenic mouse, you get
back the lineage of the original cell. So the structure of the
antigen receptor determines a number of characteristics of
these lineages, and I think that is what brings them together
under the innate-like lymphocyte denomination.
 
MK: 
 
One of the types of cells that I want to add to the list
is CD8
 
  
 
-expressing IELs that have the 
 
  
 
 TCR recep-
tor. We were involved a couple of years ago in showing
that these cells require self-recognition in the thymus in or-
der to develop (everybody used to think that they were ex-
trathymic) (17). One of the unusual things about the
CD8
 
  
 
 IELs is that although they are oligoclonal in their
repertoire, they do not always have a conserved repertoire
between individual mice. Another population that is sup-
posed to be self-reactive is the CD25
 
 
 
 CD4
 
 
 
 regulatory T
cells. At least those that are in the thymus are supposed to
have gone through a self-recognition process, but they ap-
parently have a very broad repertoire of receptors. So not
all self-reactive cells that escape negative selection necessar-
ily fit into something that is obviously an innate type lym-
phocyte. An extreme would be the 
 
  
 
 cells that live in the
mouse skin: they have one receptor and there is no N re-
gion diversity in the rearrangements, so there is very little
overall antigen receptor diversity. Other 
 
  
 
 T cells have
substantial structural diversity. It is useful to think about
how these different cells might relate to autoimmunity.
The idea used to be that they might be forming a bridge
between innate and adaptive immunity. But what most
people are thinking now, at least for NKT cells, is that they
are components of what we might call the innate immune
system, like dendritic cells and other cell types that have
adjuvant-like effects on the adaptive immune response.
 
MBB:
 
 You can appreciate the innate features that stand
out, and Albert [AB] emphasizes that these cells share. But I
also agree with Mitch [MK] that these cells are somewhere
in the middle between innate and adaptive. We don’t have
a perfect word to describe them. The other point I’d like to
make comes from the K/BxN arthritis model of Diane
Mathis and Christophe Benoist. Everyone has always
thought that autoimmunity may result because the adaptive
response is in someway perturbed under particular cir-
cumstances of innate stimulation. The K/BxN model has
shown us that things can also go the other way, that if you
have autoimmune T cell–B cell cognate self-antigen reac-
tivity, the autoantibodies that are generated can activate the
innate immune system through Fc receptors and comple-
ment receptors (18). I always thought about autoimmunity
being initiated during or following an innate reaction.
Now you also have to appreciate it the other way round:
when self-reactivity occurs in adaptive immunity it may
drive activation of NKT cells, 
 
  
 
 T cells, mast cells, mac-
rophages, and other innate cells that drive the inflammatory
response.
 
Can Innate Immunity Link Cell Death 
to Autoimmunity?
J-FB: 
 
In the NOD mouse, there is a wave of 
 
 
 
-cell apop-
tosis at 2–3 weeks of age, and it has been claimed that this
could play a role in stimulating the anti–
 
 
 
 cell response
(19). There has been a similar observation in lupus where
apoptotic cells seem to be stimulatory in various conditions
(20). How do the apoptotic cells stimulate the autoimmune
response?
 
MJS:
 
 The key, at least the way we are looking at it in lu-
pus, is that the focusing on particular autoantigens is be-
cause these are the autoantigens that can provide B cells
with an innate immune signal. Although B cells are not
considered to be innate cells, they have innate receptors.
Even in the K/BxN model, the question is still how do
you get that productive T–B interaction in the first place?
My feeling is that you need an innate immune signal to get
that interaction. Our hypothesis has been that antigens like
DNA are capable of providing B cells with a TLR signal at
the same time. With Ann Marshak-Rothstein, we have
shown that rheumatoid factor B cells and anti–chromatin B
cells in vitro can be stimulated to give an unusual B cell
immune response: a lot of autoantibody right away and not
very much of a germinal center type response (1, 21). I
think that may be down stream of the failure to clear apop- 
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totic cells or situations that create a lot of apoptotic cells.
But there’s no published data that really shows, at least in
lupus, the role of TLRs in the onset of autoimmune dis-
ease. Our lab has been trying to test this.
 
Harvey Cantor:
 
 I’ve been impressed by the finding that
uptake of apoptotic cells by plasmacytoid dendritic cells in
association with ligation of TLR9 induces the cell to pro-
duce very high levels of interferon-
 
 
 
 (22), which seems to
stimulate the activity of conventional dendritic cells and
enhance their ability to present autoantigen. I wonder if a
common thread in the development of autoimmunity, par-
ticularly after viral infection, might be these fascinating se-
quelae that seem to occur after subpopulations of DCs are
activated.
 
NK Cells and NK Receptors in Autoimmunity
Lewis L. Lanier:
 
 CD8
 
 
 
 T cells express a lot of NK recep-
tors, and many of their ligands are in fact self molecules: for
example, the ligand of the 2B4 (CD244) receptor is CD48,
a cell surface glycoprotein expressed on many normal tis-
sues (23). In addition, a lot of the NK cell receptors recog-
nize MHC class I itself. Normally, NK cells are held in
check by negative regulation by inhibitory receptors for
MHC class I. To overcome that you can either diminish
the ligands of the inhibiting receptors (that is MHC class I),
or you can just jack up the density of the ligands for the ac-
tivating receptors. In general, many of the autoimmune
phenomena we are talking about maybe explainable by a
tipping of that balance in T cells.
 
J-FB: 
 
What do you know about the regulation of expres-
sion of these ligands?
 
David H. Raulet:
 
 For MICA/B there is evidence suggest-
ing there is some transcriptional level regulation of the
ligands for the NKG2D receptor (24), but I also think that
there may be some protein level regulation of other ligands.
 
LLL:
 
 TLR signals certainly regulate this family of ligands
for NKG2D. We looked at mouse peritoneal macrophages
and demonstrate up-regulation of the RAE-1 ligands (25),
but many other types of cells in tissues that are involved in
autoimmune disorders have TLRs. There is a nice paper
from Tom Spies’ group looking at the synovial tissues of
rheumatoid arthritis patients (26). They saw overexpression
of MICA/B. It’s phenomenology, but it’s suggestive.
 
HC:
 
 In terms of the concept of an autoimmune attack
against a particular subset of cells through decreased inhibi-
tory receptor activity, you find that if you knock out the
ligand that normally interacts with inhibitory NKG2A, -C,
and -D receptors, the activated CD4 T cells, which nor-
mally express these ligands, are no longer allowed to be-
come memory cells because now they are susceptible to
NK cell activity (unpublished data). The result is an inabil-
ity to generate immunological memory.
 
LLL:
 
 The most striking inhibitory receptor I know about
is SIRP
 
 
 
, which is an inhibitory receptor expressed on
macrophages. Its ligand is CD47, which is found on lots of
tissues. If you take red blood cells from CD47 knockout
mice and put them into wild-type animals, the macro-
phages eat them immediately and cause autoimmune hemo-
lytic anemia (27).
 
MK:
 
 What about the NK cell itself? Do you find evidence
for a role in autoimmunity?
 
DHR:
 
 I don’t have any specific evidence in terms autoim-
munity, but certainly there is a lot of evidence that NK
cells regulate dendritic cells in positive and negative ways.
 
LLL:
 
 Diane Mathis had a paper where they depleted NK
cells in NOD mice and they prevented diabetes (28). The
reason Diane did this was that NK cells are one of the first
infiltrating cells in the pancreas. Obviously, they can’t cause
disease by themselves because NOD-SCID mice don’t get
sick, so there must be some back and forth with T cells.
But it changed my opinion because I previously had
thought NK cells were bystanders in the disease process.
 
The 
 
JEM
 
 is grateful to Ideashop organizers, Matthias von Herrath and
Eli Sercarz, and sponsor, Kirin Brewery, for allowing the journal to
participate. We apologize to the discussion participants whose contri-
butions could not be included owing to limitations of space. The
transcript was edited by Jennifer Bell and approved by all participants.
 
Glossary
 
 
 
-gal-cer: 
 
 
 
-Galactosyl ceramide; a glycosphingolipid originally
isolated from a marine sponge, which binds to CD1d and is rec-
ognized by a subset of NKT cells in this context.
 
CD1d:
 
 MHC class I–like molecule that can present nonpeptide
antigens and is recognized by NKT cells.
 
IEL:
 
 Intraepithelial lymphocytes; found within the intestinal epi-
thelium.
 
K/BxN:
 
 Mice transgenic for a TCR recognizing an epitope of
bovine RNase bred onto a NOD background, which develop a
disease resembling rheumatoid arthritis. Disease is transferable by
autoantibodies in the animals’ sera specific for the ubiquitous self-
antigen glucose-6-phosphate isomerase.
 
MAIT cells:
 
 Mucosal-associated invariant T cells; located in the
gut lamina and restricted by the MHC class I–like molecule MR1.
 
MICA/B:
 
 Human MHC class I–like ligands for the activating
NK receptor NKG2D, which may be induced under conditions
of cellular stress.
 
NOD mice:
 
 Nonobese diabetic; a spontaneous mouse model of
autoimmune diabetes.
 
OCH:
 
 A synthetic variant of 
 
 
 
-gal-cer that has been reported to
induce Th2-like responses.
 
RIP-LCMV mice:
 
 Rat insulin promoter–LCMV glycoprotein
transgenic mice; a viral-induced model of autoimmune diabetes.
 
SJL mice:
 
 Mouse strain highly susceptible to the induction of
experimental autoimmune encephalitis, an animal model of mul-
tiple sclerosis.
 
TLRs:
 
 Toll-like receptors; a family of innate immune receptors
that recognize various molecular patterns associated with pathogens. 
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